Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
An open-label pilot Phase 1b/2a trial (NCT01287195) administered oral OKT3 at 12 mg daily with omeprazole for 30 days to patients aged 1865 with moderate-to-severe active UC (MS 6-12), excluding those on biologics or immunomodulators within four weeks
Cancer 102 , 561569 (2010)
Leaky brain in neurological and psychiatric disorders: drivers and consequences
Implement remote patient management tools : Chat-based symptom trackers, wearable integration, and smart scale integration can be game changers, allowing for continuous monitoring and improved patient outcomes
US$ 22.78
US$ 21.95
US$ 26.89
US$ 24.55
US$ 24.16
US$ 29.43
US$ 25.60
US$ 26.04
US$ 23.72
US$ 21.38
US$ 26.83
US$ 29.33
US$ 27.75
